Search

Your search keyword '"Hurtado-Guerrero, R."' showing total 118 results

Search Constraints

Start Over You searched for: Author "Hurtado-Guerrero, R." Remove constraint Author: "Hurtado-Guerrero, R." Database MEDLINE Remove constraint Database: MEDLINE
118 results on '"Hurtado-Guerrero, R."'

Search Results

1. Loop engineering of enzymes to control their immobilization and ultimately fabricate more efficient heterogeneous biocatalysts.

2. Development of a FUT8 Inhibitor with Cellular Inhibitory Properties.

3. Mammalian cell-based production of glycans, glycopeptides and glycomodules.

4. Rational Design of Dual-Domain Binding Inhibitors for N -Acetylgalactosamine Transferase 2 with Improved Selectivity over the T1 and T3 Isoforms.

5. Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes.

6. Broad Protection against Invasive Fungal Disease from a Nanobody Targeting the Active Site of Fungal β-1,3-Glucanosyltransferases.

7. Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality.

8. Synthesis and immunological evaluation of TLR1/2 ligand-conjugated RBDs as self-adjuvanting vaccine candidates against SARS-CoV-2.

9. RTS,S/AS02A Malaria Vaccine-Induced IgG Responses Equally Recognize Native-Like Fucosylated and Nonfucosylated Plasmodium falciparum Circumsporozoite Proteins.

11. Seroprevalence of anti-SARS-CoV-2 antibodies in household domestic ferrets (Mustela putorius furo) in Spain, 2019-2023.

12. The dynamics of neutralizing antibodies against SARS-CoV-2 in cats naturally exposed to virus reveals an increase in antibody activity after re-infection.

13. Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses.

14. Polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) isozyme surface charge governs charge substrate preferences to modulate mucin type O-glycosylation.

15. Molecular basis for bacterial N-glycosylation by a soluble HMW1C-like N-glycosyltransferase.

16. A cross-sectional serosurvey of SARS-CoV-2 and co-infections in stray cats from the second wave to the sixth wave of COVID-19 outbreaks in Spain.

17. Molecular Recognition of GalNAc in Mucin-Type O-Glycosylation.

18. Identification of global inhibitors of cellular glycosylation.

19. O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern.

20. The Essential Role of Water Molecules in the Reaction Mechanism of Protein O-Fucosyltransferase 2.

21. No Evidence of SARS-CoV-2 Infection in Wild Mink ( Mustela lutreola and Neogale vison ) from Northern Spain during the First Two Years of Pandemic.

22. Structural and mechanistic insights into the cleavage of clustered O-glycan patches-containing glycoproteins by mucinases of the human gut.

23. O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.

24. Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment.

25. Structural basis for the synthesis of the core 1 structure by C1GalT1.

26. Serological evidence of SARS-CoV-2 and co-infections in stray cats in Spain.

27. Atomic and Specificity Details of Mucin 1 O -Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.

28. Anticancer and Structure Activity Relationship of Non-Symmetrical Choline Kinase Inhibitors.

29. NleB/SseK-catalyzed arginine-glycosylation and enteropathogen virulence are finely tuned by a single variable position contiguous to the catalytic machinery.

30. FUT8-Directed Core Fucosylation of N-glycans Is Regulated by the Glycan Structure and Protein Environment.

31. Asparagine Tautomerization in Glycosyltransferase Catalysis. The Molecular Mechanism of Protein O -Fucosyltransferase 1.

32. Absence of SARS-CoV-2 Antibodies in Natural Environment Exposure in Sheep in Close Contact with Humans.

33. Protein O -Fucosyltransferase 1 Undergoes Interdomain Flexibility in Solution.

34. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2.

35. SARS-CoV-2 Seroprevalence in Household Domestic Ferrets ( Mustela putorius furo ).

36. Recent advances in the design of choline kinase α inhibitors and the molecular basis of their inhibition.

37. Fucosyltransferase-specific inhibition via next generation of fucose mimetics.

38. Self-acetylation at the active site of phosphoenolpyruvate carboxykinase (PCK1) controls enzyme activity.

39. Structural characterization of an unprecedented lectin-like antitumoral anti-MUC1 antibody.

40. Synthesis, biological evaluation, in silico modeling and crystallization of novel small monocationic molecules with potent antiproliferative activity by dual mechanism.

41. Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation.

42. Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N -Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.

43. Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology.

44. A Bump-and-Hole Approach to Dissect Regulation of Protein O-Glycosylation.

45. Synthesis, conformational analysis and in vivo assays of an anti-cancer vaccine that features an unnatural antigen based on an sp 2 -iminosugar fragment.

46. A mechanism-inspired UDP- N -acetylglucosamine pyrophosphorylase inhibitor.

47. Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.

48. Structural basis for substrate specificity and catalysis of α1,6-fucosyltransferase.

49. Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.

50. Polypeptide GalNAc-Ts: from redundancy to specificity.

Catalog

Books, media, physical & digital resources